PT3429559T - Composições palatáveis incluindo fenilbutirato de sódio e suas utilizações - Google Patents

Composições palatáveis incluindo fenilbutirato de sódio e suas utilizações

Info

Publication number
PT3429559T
PT3429559T PT168947869T PT16894786T PT3429559T PT 3429559 T PT3429559 T PT 3429559T PT 168947869 T PT168947869 T PT 168947869T PT 16894786 T PT16894786 T PT 16894786T PT 3429559 T PT3429559 T PT 3429559T
Authority
PT
Portugal
Prior art keywords
compositions including
including sodium
sodium phenylbutyrate
palatable compositions
palatable
Prior art date
Application number
PT168947869T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Acer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc filed Critical Acer Therapeutics Inc
Publication of PT3429559T publication Critical patent/PT3429559T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PT168947869T 2016-03-15 2016-10-17 Composições palatáveis incluindo fenilbutirato de sódio e suas utilizações PT3429559T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15

Publications (1)

Publication Number Publication Date
PT3429559T true PT3429559T (pt) 2022-07-20

Family

ID=59847918

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168947869T PT3429559T (pt) 2016-03-15 2016-10-17 Composições palatáveis incluindo fenilbutirato de sódio e suas utilizações

Country Status (22)

Country Link
US (6) US20170266115A1 (https=)
EP (2) EP4104822A1 (https=)
JP (4) JP7136763B2 (https=)
KR (3) KR20250150154A (https=)
AU (1) AU2016398029B2 (https=)
BR (1) BR112018068665B1 (https=)
CY (1) CY1125450T1 (https=)
DK (1) DK3429559T3 (https=)
ES (1) ES2922749T3 (https=)
HR (1) HRP20220856T1 (https=)
HU (1) HUE059630T2 (https=)
IL (3) IL296490B2 (https=)
LT (1) LT3429559T (https=)
MX (2) MX391305B (https=)
PL (1) PL3429559T3 (https=)
PT (1) PT3429559T (https=)
RS (1) RS63383B1 (https=)
SA (1) SA518400020B1 (https=)
SG (1) SG11201807979SA (https=)
SI (1) SI3429559T1 (https=)
SM (1) SMT202200386T1 (https=)
WO (1) WO2017160345A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250150154A (ko) 2016-03-15 2025-10-17 에이서 테라퓨틱스 인크. 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CA3184989A1 (en) * 2020-07-07 2022-01-13 Christopher D. Schelling Methods of administering taste masked phenylbutyrate and compositions therefor
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー-エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型
IL315049A (en) * 2024-08-15 2026-03-01 Prilenia Neurotherapeutics Ltd Taste-masking compounds containing pridopidine, their use and method for their preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) * 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US8236349B2 (en) * 2004-04-12 2012-08-07 Bend Research Inc. Taste-masked drugs in rupturing multiparticulates
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
EP2954780A1 (en) * 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
CA2820178A1 (en) 2010-12-06 2012-06-14 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US8897280B2 (en) * 2011-03-29 2014-11-25 Qualcomm Incorporated System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols
EP2709593A4 (en) * 2011-05-16 2014-10-29 Sun Pharma Advanced Res Co Ltd PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES
JP2012240917A (ja) * 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
AU2012265842A1 (en) 2011-06-07 2014-01-23 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
WO2012175714A1 (en) * 2011-06-22 2012-12-27 Gmp-Orphan Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease
AR089645A1 (es) * 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) * 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN110302168A (zh) 2013-01-28 2019-10-08 万平 定位速释生物粘附剂及其制备方法和应用
JP6147711B2 (ja) * 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
KR20250150154A (ko) 2016-03-15 2025-10-17 에이서 테라퓨틱스 인크. 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도

Also Published As

Publication number Publication date
EP3429559A4 (en) 2019-11-06
KR102690703B1 (ko) 2024-08-02
MX2022003969A (es) 2022-04-25
AU2016398029B2 (en) 2023-03-02
SG11201807979SA (en) 2018-10-30
MX2018011229A (es) 2019-05-30
IL296490B1 (en) 2025-09-01
AU2016398029A1 (en) 2018-10-11
HRP20220856T1 (hr) 2022-10-14
KR102865751B1 (ko) 2025-09-29
US20210220304A1 (en) 2021-07-22
JP7136763B2 (ja) 2022-09-13
LT3429559T (lt) 2022-08-10
CY1125450T1 (el) 2025-05-09
EP3429559B1 (en) 2022-04-13
RS63383B1 (sr) 2022-08-31
BR112018068665A2 (pt) 2019-02-05
US20230133629A1 (en) 2023-05-04
ES2922749T3 (es) 2022-09-20
IL296490B2 (en) 2026-01-01
SMT202200386T1 (it) 2022-11-18
JP2026027401A (ja) 2026-02-18
BR112018068665B1 (pt) 2023-12-26
EP4104822A1 (en) 2022-12-21
MX391305B (es) 2025-03-21
US20170266115A1 (en) 2017-09-21
JP2024081748A (ja) 2024-06-18
JP2019509345A (ja) 2019-04-04
US11433041B2 (en) 2022-09-06
IL322955A (en) 2025-10-01
KR20190008840A (ko) 2019-01-25
CA3017573A1 (en) 2017-09-21
US11202767B2 (en) 2021-12-21
EP3429559A1 (en) 2019-01-23
WO2017160345A8 (en) 2018-02-22
IL261777A (en) 2018-10-31
SI3429559T1 (sl) 2022-11-30
US11154521B2 (en) 2021-10-26
KR20240119184A (ko) 2024-08-06
US20200261385A1 (en) 2020-08-20
IL261777B2 (en) 2023-02-01
SA518400020B1 (ar) 2022-12-21
HUE059630T2 (hu) 2022-11-28
JP2022106927A (ja) 2022-07-20
DK3429559T3 (da) 2022-07-11
US20210186908A1 (en) 2021-06-24
IL296490A (en) 2022-11-01
PL3429559T3 (pl) 2022-11-07
KR20250150154A (ko) 2025-10-17
US20260076927A1 (en) 2026-03-19
IL261777B (en) 2022-10-01
WO2017160345A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
EP3513809A4 (en) MEDICAL COMPOSITION
MA50657A (fr) Formulations de niraparib
PT3429559T (pt) Composições palatáveis incluindo fenilbutirato de sódio e suas utilizações
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
DK3655038T3 (da) Farmaceutisk sammensætning
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
DK3244878T3 (da) Faste orale sammensætningsformer
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
EP3646858A4 (en) ENCLOSED FORMULATIONS
EP3600279A4 (en) 1-amino-1-cyclopropanecaboxylic acid formulations
DK3583943T3 (da) Farmaceutisk sammensætning
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
IL264445A (en) Compounds and compositions and uses thereof
HUE063178T2 (hu) Kopanlizib formulációi
MA49837A (fr) Compositions pharmaceutiques
IL272167A (en) Hemopexin formulations
SMT202400478T1 (it) Composizione farmaceutica
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf
EP3727418A4 (en) SURFACTANT FORMULATIONS FOR INHALATION
EP3658161A4 (en) USED TURMERIC - PROCESS AND COMPOSITIONS THEREOF
EP3305309A4 (en) ANTICARIOGENIC AGENT AND ANTICARIAC COMPOSITION
EP3710069A4 (en) COMPOSITIONS OF FLUORESCEIN AND BENOXINATE